Form 4: Akero Therapeutics CEO Andrew Cheng Sells 30,000 Shares

Akero Therapeutics' CEO, Andrew Cheng, sold 30,000 shares of common stock on April 10, 2025, at a weighted average price of $35.226 per share.

Summary

• On April 10, 2025, Andrew Cheng, the President and CEO of Akero Therapeutics, Inc. (AKRO), sold 30,000 shares of common stock.
• The sale was executed at a weighted average price of $35.226 per share.
• The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan established on August 16, 2024.
• Following the reported transaction, Andrew Cheng still beneficially owns 624,324 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a standard disclosure of an insider stock sale under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's performance.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It's common for executives to sell shares periodically for personal financial management, often under pre-arranged trading plans to avoid accusations of trading on inside information. The impact on the stock price is usually minimal unless the sale is unusually large or coincides with other negative news.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Akero Therapeutics, Andrew Cheng, stock sale, Form 4, AKRO, Rule 10b5-1, insider trading